

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (HI-151)	DABOCEMAGENE AUTOFICEL
PRONUNCIATION	dab" oh sem' a jeen aw" toe fye' sel
THERAPEUTIC CLAIM	Treatment of dystrophic epidermolysis bullosa

PRODUCT DESCRIPTION

DNA (recombinant lentivirus vector INXN-2004-transduced human autologous dystrophic epidermolysis bullosa dermal fibroblast cell FCX-007 integrated proviral human collagen type VII transgene COL7A1 plus 5'-human cytomegalovirus promoter/UTR- and 3'-LTR/polyA signal-containing flanks) (CAS NAME)

FCX-007 Drug Product (DP) consists of a suspension of autologous type VII collagen- deficient Dystrophic Epidermolysis Bullosa (DEB) human dermal fibroblast (HDF) cells. The DEB HDF cells are gene-modified using INXN-2004, a lentivirus encoding the human wild type COL7A1 gene (type VII collagen).

CAS NUMBER	2365353-63-3
TRADEMARK	None as yet
SPONSOR	Castle Creek Biosciences, LLC
CODE DESIGNATIONS	FCX-007
UNII	0S9A4XK1WT
WHO NUMBER	11676

SCS